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Cx. Incorporation of ctDNA analysis into routine follow-up for early detection of
relapse may allow earlier initiation of alternate treatment modalities.
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Background:HER2 oncogene amplification, being accompanied by its overexpression,
is an established driver event in breast and gastric carcinomas. The functional role of
HER2 in pathogenesis of other tumor types is less defined.
Methods: 2401 archival samples of lung carcinomas (LC) and 1969 samples of colorec-
tal carcinomas (CRC) were subjected to HER2 copy number analysis. Selected tumors
with amplification of this oncogene were further subjected to HER2 immunohisto-
chemistry andmRNA quantitation. In addition, the expression levels of some neigh-
bouring genes located in 17q12-21 amplicon were analyzed.
Results: Frequency of HER2 amplification was similar in both groups, being 100/2401
(4.2%) in LC and 84/1969 (4.3%) in CRC, respectively. 10 (82%) out of 12 analyzed
HER2-amplified CRCs demonstrated clear evidence for HER2 protein andmRNA
overexpression, while this estimate approached to only 3 (27%) out of 11 for LCs.
Expression analysis of GRB7, STARD3, and LASP1 revealed a statistically significant
correlation betweenHER2 and STARD3 levels [r¼ 0.571, Spearman test]. High
STARD3 expression was observed in HER2-amplified CRCs but not LCs [p¼ 0.03].
Conclusions:HER2 amplification is frequently accompanied by gene overexpression
in colorectal but not lung adenocarcinomas. STARD3 gene belonging to 17q12-21
amplicon demonstrates evidence for activation in HER2-amplified colorectal neo-
plasms and therefore deserves further analysis.
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Background: The androgen receptor splice variant 7 (AR-V7) is strongly associated
with resistance to hormonal therapy (HT) in castration-resistant prostate cancer
(CRPC), although it is not implemented in clinical practice as a biomarker. The AR-full
length (AR-FL) is also overexpressed in CRPC but its role has yet to be clarified. The
aim of the present work was to investigate the role of AR-V7 and AR-FL as predictors of
resistance to HT in plasma-derived exosomal RNA.
Methods: 6ml of blood were collected in EDTA tubes before the start of abiraterone/
enzalutamide; blood was centrifuged and plasma stored at -80 C until analysis.
Exosomes isolation and RNA extraction were performed using the exoRNeasy kit
(Qiagen) as per manufacturer instructions. The analysis of AR-FL and AR-V7 were per-
formed by digital droplet PCR using the One-Step RT-ddPCR kit (BioRad). The abso-
lute target concentration as copies/ml in samples was calculated by ddPCRQuantaSoft
and statistical analyses were performed by SPSS v.24.
Results: 52 patients (pts) were enrolled; AR-FL was detected in all pts (median: 700
copies/ml), while 15 subjects (28.8%) were AR-V7þ (median: 310 copies/ml) at base-
line. The amount of AR-FL was significantly higher in pts AR-V7þ vs AR-V7- (6700 vs
490 copies/ml, p< 0.0001). Median PFS and OS were longer in AR-V7- vs AR-V7þ pts
(median PFS 25 vs 4mo, p< 0.0001; median OS 38 vs 9mo, p< 0.0001). A ROC curve
was calculated for AR-FL in the overall population and 950 copies/ml was identified as
cut-off value. Pts were then stratified across this value and it was found that PFS was
22mo in pts with<950AR-FL copies/ml vs 4mo in pts with950 copies/ml
(p¼ 0.0003). In 12/15 AR-V7þ pts the AR-FL expression was950 copies/ml while in
3/15 AR-V7þ pts, AR-FL expression was<950 copies/ml; however, their PFS reflected
the AR-V7 better than AR-FL status, being, respectively 6, 10, 4mo. No other clinical
variables were correlated with worse PFS at the univariate analysis (i.e. Gleason score
7 vs> 7, age).
Conclusions: This study demonstrates that resistance to HTmay be predicted by AR-
V7, making it a clinically relevant biomarker. AR-FL over-expressionmay contribute to
hormone resistance although AR-V7 plays a primary role.
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Background:Brainmetastases (BM) are themost common intracranial tumors affecting
about 8-10% of all cancer patients.Morphology and immunohistochemical staining are
two common approaches used to identify the primary sites of BM samples, butmorphol-
ogy fails to identify poorly differentiated tumors and IHCmarkers usually lack specificity.
About 2% to 14% of BMpatients still present with unknownprimary sites. A 90-gene assay,
proposed in our previous study, is an RNA-based gene expression test to identify the tissue
of origin in poorly differentiated and undifferentiated tumors. This study aims to evaluate
the performance of the 90-gene assay in determining the primary sites for BM samples.
Methods: The sequence-based gene expression profiles of 708 primary brain tumors
(PBT) collected from The Cancer Genome Atlas database were performed by a 90-gene
expression signature, with a similarity score for each of 21 tumor types. We used
Optimal Binning algorithm to generate a threshold for separating PBT from BM.
Eighteen PBT samples from Fudan University Shanghai Cancer Center were analyzed
to substantiate reliability of the threshold. In addition, the performance of the 90-gene
assay for identifying the tissue of origin was validated in a cohort of 48 BM samples
with known origin from The First Affiliated Hospital, Zhejiang University. For each
BM sample, the tumor type with the highest similarity score was considered tissue of
origin. When a sample was diagnosed as PBT but the similarity score below the thresh-
old, the second prediction was considered as primary site.
Results: A threshold of the similarity score, 70, was identified to discriminate PBT from
BM (PBT: 70, BM:< 70) with an accuracy of 99% (703/708). Eighteen PBT and 44
BMwere performed by the 90-gene assay. The results of 18 PBT samples matched refer-
ence diagnosis with a concordance rate of 100% and all similarity scores were above 70.
Of 44 BM samples, the 90-gene assay accurately predicted primary sites in 89% (39/44,
95%CI: 0.75-0.96) of the cases.
Conclusions: The 90-gene assay showed promising discriminatory ability to separate
PBT from BM and identify the primary site of BM. Our findings demonstrated the
potential that 90-gene assay can serve as a powerful tool for accurately identifying the
tissue of origin for BM samples.
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Background: A newmultiplexed biomarker panel is being developed for detection of
microsatellite instability (MSI) that is more sensitive than currently available systems.
Preliminary research data shows increasedMSI sensitivity for colon polyps and
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